Comparing the Effects of Commercially Available Dietary Supplements on CoQ10 Concentrations

NCT ID: NCT06640465

Last Updated: 2025-08-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2/PHASE3

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-12

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this study is to compare the safety and effectiveness of commercially available dietary supplements believed to increase coenzyme Q10 (CoQ10) concentrations.

An 8-week, randomized, placebo-controlled clinical trial will be conducted comparing the effectiveness of four commercially available dietary supplements on increasing CoQ10 concentrations and self-reported health outcomes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Wellness Health

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ubiquinol + geranylgeraniol combination (Designs for Health - CoQnol™ 200)

Group Type EXPERIMENTAL

Ubiquinol + geranylgeraniol

Intervention Type DIETARY_SUPPLEMENT

Combination of ubiquinol and geranylgeraniol

Geranylgeraniol (Annatto-GG™ 300)

Group Type EXPERIMENTAL

Geranylgeraniol

Intervention Type DIETARY_SUPPLEMENT

Geranylgeraniol alone

Ubiquinol (Jarrow Formulas QH-absorb® 200 mg)

Group Type EXPERIMENTAL

Ubiquinol

Intervention Type DIETARY_SUPPLEMENT

Ubiquinol alone

Ubiquinone (NOW CoQ10 200mg)

Group Type EXPERIMENTAL

Ubiquinone

Intervention Type DIETARY_SUPPLEMENT

Ubiquinone alone

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ubiquinol + geranylgeraniol

Combination of ubiquinol and geranylgeraniol

Intervention Type DIETARY_SUPPLEMENT

Geranylgeraniol

Geranylgeraniol alone

Intervention Type DIETARY_SUPPLEMENT

Ubiquinol

Ubiquinol alone

Intervention Type DIETARY_SUPPLEMENT

Ubiquinone

Ubiquinone alone

Intervention Type DIETARY_SUPPLEMENT

Placebo

Placebo capsule

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adult males or females age ≥ 40 years
2. Ability to read and speak English

Exclusion Criteria

1. Daily use within the past 2 months of any dietary supplements containing CoQ10 or geranylgeraniol (GG)
2. Taking a statin medication within the past 6 months
3. Current daily usage of H2 blockers or PPI medications
4. Current daily use of bisphosphonates
5. Current daily tobacco smoker
6. Known allergies to any substance in the study products
7. Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks
8. Current diagnosis of a chronic health condition (e.g., cancer, Crohn's disease) deemed clinically contraindicated for the study protocol.
9. Participant in a clinical trial in the previous 30 days.
10. Participants unable to provide consent
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

OvationLab

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

True Health Center for Precision Medicine

El Dorado Hills, California, United States

Site Status

Cornerstone Health Community

Centennial, Colorado, United States

Site Status

CTMD Research

Palm Springs, Florida, United States

Site Status

Functional Medicine of Idaho

Eagle, Idaho, United States

Site Status

New Dawn Wellness and Medical Center

Houston, Texas, United States

Site Status

Vida Integrated Health

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OvationLab

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

UCSD Q10 and Aging Study
NCT02012322 COMPLETED NA
Q10 for Gulf War Veterans
NCT01011348 COMPLETED NA